Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT(R) (avapritinib) in Indolent Systemic Mastocytosis

Blueprint Medicines, a Sanofi company, today announced AYVAKIT(R) (avapritinib) data showing clinically meaningful outcomes and a w ...

Rare Genetic Disease Discovered in Ancient Skeletal Embrace From The Ice Age

It also allowed the team to diagnose the younger of the pair with acromesomelic dysplasia, Maroteaux type (AMDM), a rare genetic disorder affecting the growth of bones. This is the earliest evidence ...
dvm360

Fetch Charlotte: Lectures to attend

Plan your Fetch Charlotte schedule with these lectures to watch.
The Malaysian Reserve

Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indo…

Real-world study of AYVAKIT highlights improvement across ISM symptoms ---- 12 data presentations at 2026 AAAAI Annual ...